



University  
of Basel

Faculty of  
Medicine



# European Center of Pharmaceutical Medicine

CAS/DAS in Pharmaceutical Medicine  
MAS in Medicines Development

2019–2021

**ECPM**<sup>®</sup>  
European Center of Pharmaceutical Medicine

ADVANCED STUDIES

## Table of Contents

Mission	4
Pharmaceutical medicine	4
Modular training platform	4
Training in pharmaceutical medicine	5
Syllabus: IMI PharmaTrain	5
Unique programme features	5
Learning outcomes	5
Target audience	6
Admission criteria	6
Organisers	6
Teaching faculty	6
Diploma Course structure	6
Course dates	6
University network	7
Final examination	8
Diploma Modules 1–6	9–14
Learning methods	15
Course materials	15
Mediathek	15
Diploma Course	16
Master Course	16
Registration	17
Cancellation policy	17
Course venue	17
Accommodation	17
ECPM alumni	18
Advisory board	18
University of Basel	18

### Under the auspices of

EUCOR the European Campus

IFAPP, International Federation of Associations of Pharmaceutical Medicine

Accredited by SwAPP/ SGPM

Recognised as PharmaTrain Centre of Excellence



# Invitation

The European Center of Pharmaceutical Medicine (ECPM) is dedicated to be the leading university institute for medicines and drug development in Europe. ECPM was founded in 1991 to cover the training needs of specialists working in drug development. We offer a range of different training programmes to provide a holistic understanding of the drug, medicines or device development process from discovery to the benefit of patients including key concepts in clinical trials, regulatory science and marketing.

The ECPM Diploma Course (ECPM Course) in Pharmaceutical Medicine represents our core of the postgraduate training platform and offers a modular extension with single modules to achieve a Master of Advanced Studies in Medicines Development. The programmes are targeted at representatives from industry, service industry, academic and government decision- and policy-makers who already have a good grounding in the basics and will benefit from a more in-depth, comprehensive

and systematic immersion into modern medical product and device development, regulation and market introduction.

ECPM belongs to the department of public health of the medical faculty at the University of Basel and operates with partners worldwide. The ECPM is accredited as IMI PharmaTrain Centre of Excellence and acknowledged by the International Federation of Associations of Pharmaceutical Physicians (IFAPP).

Participation in the ECPM training programmes provide the opportunity to integrate work and education, to discuss with experts face-to-face or online, to gain in-depth knowledge and enhance your expertise while building a professional network, and to put this into perspective with your own career plan.

An international faculty of experts from academia, pharmaceutical and biotechnology companies and regulatory authorities carry the teaching responsibility.

We cordially invite you to participate in the ECPM course.



Prof. Thomas D. Szucs  
Director



Dr. Annette Mollet  
Head of Education & Training



Dr. Katja Suter  
Course Director

# Life Long Learning

## Modular training parallel to work.



### Workplace of students

(2017–2019)

Big Pharma	57.4 %
Academia	20.4 %
Biotech and Small Pharma	11.1 %
CRO	4.6 %
Health Authority	6.5 %
<b>Total</b>	<b>100 %</b>

Total no of students 108

### Mission

Our mission is to offer the best international training platform to provide and enhance the knowledge, expertise and skills needed to perform modern discovery, development, regulation and marketing of medical products. An outstanding faculty teaches integrating cutting-edge concepts and best practices to enable the development of efficient, economical, high quality and safe medical products for the benefit of the patients and the society. ECPM is constantly innovating to offer Swiss excellence with a global perspective.

### Pharmaceutical medicine


“Pharmaceutical Medicine is the scientific discipline for the discovery, development, evaluation, registration, monitoring and medical marketing of medicines for the benefit of the patients” (IFAPP)

### Modular training platform

This à la carte system allows attending continuing education courses while working to transfer knowledge between theory and real world experience. The European credit transfer system (ECTS), known as the Bologna system, was established in 1999 by education ministers of 29 European countries.

ECTS is a learner-centred system for credit accumulation and transfer, based on the principle of transparency of the learning, teaching, and assessment processes and harmonises the European title system. Following the graduate Bachelor or Master title, the first postgraduate level is the CAS (Certificate of Advanced Studies, 10-20 ECTS), the second is the DAS (Diploma of Advanced Studies, 30 ECTS) and finally the MAS (Master of Advanced Studies, at least 60 ECTS).

The MAS is composed of three parts (60 ECTS):





# Deepen Your Expert Knowledge

## Take your skills to the next level.

### Training in pharmaceutical medicine

Deepen your knowledge and expertise in modern medical product development, regulation and market introduction by adding your personalised modules and a master thesis to achieve a Master of Advanced Studies in Medicines Development from the University of Basel. This offers the possibility to intensify certain aspects or to fill gaps in your portfolio. The six modules and the successful examination of the diploma course (30 ECTS) form the compulsory part of the master programme. The remaining master modules (20 ECTS) can be chosen and booked à la carte (please see CPD list on [www.ecpm.ch](http://www.ecpm.ch)). Since the programme is completed in parallel to work, a study duration of maximum 5 years is possible. Participants will be registered as students of the University of Basel. The third part to achieve the MAS is the writing and the defence of the master thesis. The topic and the tutor will be defined and agreed upon with the course directorate. This will provide the final 10 ECTS to be awarded a Master of Advanced Studies in Medicines Development by the University of Basel.

### Syllabus: IMI PharmaTrain

Training in Pharmaceutical Medicine covers all aspects of pharmaceutical medicine and drug development sciences with an international scope as defined by the PharmaTrain syllabus. This includes the discovery and development of new medicines, biopharmaceutical sciences, clinical pharmacology and trial methodology, good clinical practice and ethics, pharmacovigilance and epidemiology, biostatistics, regulatory affairs, health economics, project management, marketing and new therapeutic approaches.

### Unique programme features

- Deepen your knowledge in the essentials of the medical product lifecycle – from molecule to the marketplace
- Understand the trends in global pharmaceutical development and health care environment

- Expose yourself to new innovative methods, tools and strategies and apply them in your daily work
- Become a leader and integrator for medical product development
- Create a global professional network.
- Enhance your CV by acquiring a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine and take it to the next step of a Master of Advanced Studies (MAS) in Medicines Development
- Get a Swiss speciality recognition for MDs or SwAPP diploma
- Prepare for the next career step

### Learning outcomes

On successful completion of this course in pharmaceutical medicine students should be able to demonstrate an understanding/knowledge of the following:

- the process of drug development and how to incorporate and apply the latest innovative bio-pharmaceutical development strategies, methodologies and tools
- the principal steps in drug discovery, target identification and non-clinical research
- the pertinent issues involved in the undertaking of clinical research and development
- the regulation of medicines in the various global markets, including ethical and legal provisions
- the management of drug safety issues pre- and post-marketing authorisation
- the management of all lifecycle activities (regulatory and marketing) of a medicinal product
- The principles of health economics and their application in the development and marketing of medicinal products

### Graduates

**CAS**

since 1991

1225

**DAS**

since 2001

560

**MAS**

since 2015

4

# Certificate & Diploma in Pharmaceutical Medicine

## Prepare for the next career step.



**Pharmaceutical market**

USA	41 %
Europe	13 %
Other major developed	3 %
China	11 %
Brazil/Russia/India	6 %
Other emerging countries	8 %
Rest of World	12 %
Worldwide	100 %

### Target audience

Our courses are targeted at participants from the industry, service industry, academic and government decision- and policy-makers who have a good grounding in the basics and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product development, regulation and market introduction.

### Admission criteria

In order to enroll in the ECPM diploma course, applicants must have a higher university degree, such as a Master's, MD, PharmD or PhD and a primary interest in medical product discovery, development, regulation and health care system. Applications sur dossier are possible on an individual basis. The programme is particularly aimed at professionals who are involved in the medical product development process and have at least 2 years of working experience.

### Organisers

The ECPM course is organised by the European Center of Pharmaceutical Medicine, a university institute at the medical faculty of the University of Basel, Switzerland which is also a member of the Pharmacenter Basel (Center of Pharmaceutical Sciences, University of Basel). The ECPM course

was established in 1991 in partnership with the EUCOR, European Confederation of the Upper Rhine Universities medical schools of the Universities of Basel, Freiburg i. Br. and Strasbourg and the pharmaceutical industry.

### Teaching faculty

The ECPM teaching faculty consists of about 200 international experts in regulatory sciences, medical product discovery and development, product evaluation and business practices. Lecturers and tutors will be drawn from academia, regulatory agencies (such as EMA, FDA and local agencies), pharmaceutical, diagnostic and biotechnology industry, coverage and reimbursement entities, professional societies and national institutes

### Diploma Course structure

The ECPM course programme consists of 24 face to face teaching days divided into six modules over a period of two years (eight hours per day, each lesson 45–60 minutes), including team involvement in mentored, case-oriented breakout sessions. In addition, approximately eight hours distance learning per module is required in order to prepare for the case studies. All lectures are recorded and the videos are available on the ECPM mediathek for course participants.

### Course dates

Module 1	Global Drug Development and Pharmaceutical Business Environment	02.09. – 05.09.2019
Module 2	From Non-Clinical Testing to First-in-Humans	10.02. – 13.02.2020
Module 3	Planning, Collecting and Managing Clinical Data	22.06. – 25.06.2020
Module 4	Clinical and Safety Data Evaluation and Biostatistics	07.09. – 10.09.2020
Module 5	Global Registration and Approval Process	01.02. – 04.02.2021
Module 6	Integrated Product Development, Healthcare Marketplace and Marketing	21.06. – 24.06.2021
Final Examination	Multiple choice	24.08.2021
	Oral/essay	24.08.2019 or 14.09.2021



# Master in Medicines Development & CPD

## Expand your knowledge to mastership.

The master or individual modules can be chosen according to the interest and needs of the students. They can be taken either from our training platform (see list below) or from our partner universities, which offer training relevant to drug development sciences and the IMI PharmaTrain syllabus ([www.pharmatrain.eu](http://www.pharmatrain.eu)). Before enrolling in a course at another university with the intent of having this accredited towards your masters, we strongly recommend that you contact the course directorate to ensure that the courses will be accredited. Learning outcomes of the modules are assessed individually upon completion of each module to achieve the credit points. All courses can also be booked as single courses for your continuing professional education.

Please note that programmes and topics are subject to change and constantly expanded. Many modules are being planned and offered according to market need. Please see details in [www.ecpm.ch/cpd/](http://www.ecpm.ch/cpd/)

### University network

A consortium of 21 European universities, 15 pharmaceutical companies of the European Federation of Pharmaceutical Industries Association (EFPIA), 11 learned societies (associations and agencies), 3 advisors and the EU performed a project (2009–2014) under the public private partnership of the IMI (Innovative Medicines Initiative) concerned with education and training in medicines development. ECPM was the managing entity and the achievements of the project include: shared training syllabus, shared examination standards, mutual recognition of learning outcomes and credit points (see [www.pharmatrain.eu](http://www.pharmatrain.eu)).

ECPM has established an international network and collaboration with courses in drug development and regulatory sciences. Its partner courses at Peking University Research Institute and the University of San Francisco in Washington share the same teaching principles and quality label. This unique global collaboration offers the possibility to start training at one site and continue or successfully achieve the diploma at one of the sister courses in Basel, Beijing and Washington.



**Dr Karen Cheng, Global Medical Product Lead Immunology, Shire**

“The ECPM program was the foundational program I was looking for to make my career switch, and it was highly recommended by my peers. It helps to grow the experience and knowledge that I am building every day.”

Topic	Course Format	ECTS
Communication and Presentation Skills	Onsite plus pre and post assignment	2
Ethics and Legal Aspects of Medicines Development	Onsite plus pre and post assignment	2
Follow-on drugs: Generic, Biosimilar and non-Biological Similar Medicinal Products at Semmelweis University, Budapest	Onsite plus pre and post assignment	3
Leadership and Business Development	Onsite plus pre and post assignment	3
Project Management in Medicines Development	Onsite plus pre and post assignment	4
Scientific Medical Writing	Onsite plus pre and post assignment	1
Study Trip on Different Health Care Systems	Onsite plus pre and post assignment	3
Summer Institute in Regulatory Science at the George Washington University, Washington	Onsite plus pre and post assignment	3
Health Economics	e-learning or onsite	1
Safety	e-learning	1
Personalised Healthcare	e-learning	1
<b>Total</b>		<b>24</b>



[web.ecpm.ch/overview-ecpm-courses](http://web.ecpm.ch/overview-ecpm-courses)

# Title system

## Study in an international network.



### Pharmaceutical research and development investment

(2014)	
Europe	31%
USA	36%
Japan	15.9%
Rest of World	18%
Total	100%
Total	€ 538.5bn

### Final examination

At least 80% onsite course attendance is required to sit the examination and to receive the title by the University of Basel.

The final examination is a closed book exam and will be performed on iPads onsite. A test version is available via the BeAxii App. The multiple choice examination (120 questions) will take place on August 24, 2021 from 9:00 to 13:00. Oral/essay examination can either be taken on the same day in the afternoon or on September 14, 2021.

### Certificate of Advanced Studies in Pharmaceutical Medicine (CAS): 20 ECTS

Successful completion of the two-years course cycle and passing of the final multiple choice examination will lead to a Certificate of Advanced Studies (CAS) in Pharmaceutical Medicine by the University of Basel.

### Diploma of Advanced Studies in Pharmaceutical Medicine (DAS): 30 ECTS

Successful completion of the two-years course cycle and passing the final examination consisting of

the multiple choice test, an oral and an essay writing will lead to a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine by the University of Basel. This forms the basis for the MAS in medicines development.

### Master of Advanced Studies in Medicines Development (MAS): 60 ECTS

Complementing the DAS with elective courses (20 ECTS) either from the ECPM training platform or the PharmaTrain partner Universities and writing a master thesis will lead to a Master of Advanced Studies (MAS) in Medicines Development by the University of Basel.

### Specialist in Pharmaceutical Medicine FMH or SwAPP Diploma

For MDs, the Diploma of Advanced Studies in Pharmaceutical Medicine covers the theoretical part required for the FMH (Swiss Association of Medical Doctors) speciality title in pharmaceutical medicine as defined by the Swiss Association of Pharmaceutical Physicians ([www.sgpm.ch](http://www.sgpm.ch)). The SwAPP (Swiss Association of Pharmaceutical Professionals) offers an equivalent title for people holding an MSc and/or PhD ([www.swapp.ch](http://www.swapp.ch)).



	CAS	DAS	MAS	Swiss Specialist in PM or SwAPP Diploma	CPD
6 Diploma Modules	■	■	■	■	□
MCQ Examination	■	■	■	■	□
Oral/Essay Examination	□	■	■	■	□
Single or individual modules	□	□	■	□	■
Master thesis	□	□	■	□	□
Practical work experience	□	□	□	■	□
ECTS Credits	20	30	60	30	1-5
Title	Certificate of Advanced Studies (CAS) in Pharmaceutical Medicine	Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine	Master of Advanced Studies (MAS) in Medicines Development	Specialist Title → Application with Professional Association	Certificate of Attendance



# Diploma Modules

## From Molecule to Marketplace

September 2 – September 5, 2019

### Global Drug Development and Pharmaceutical Business Environment

#### Content

Principles and organisation of global pharmaceutical research and label-driven product development. Future directions of global pharmaceutical and health economics and business environments, and implications for drug selection, drug development, regulatory and business evaluations. Innovation in discovery and development as a response to medical and market needs. Health economics and disease management and their application in the changing health care environment. Patenting of new chemical and biological compounds.

#### Key topics

- Discovering, modifying, assessing and patenting new chemical and biological compounds
- System biology and principles of translational research
- Target identification and validation
- Introduction in the drug development process and the health care environment
- Drug development for special populations
- Project and portfolio management techniques

#### Learning outcomes

At the end of this module the student should be able to outline the:

1. Principal discovery and validation steps in drug development
2. The elements, functions and the management involved in the translational research and integrated development of a new drug
3. Principles of patenting new chemical compounds



# 1

Modul 1



**Dr. Holger-Maria Rohde,**  
Teaching Faculty ECPM and  
Director Regulatory Project  
Management, Merck KGaA

“The ECPM Course in Basel develops your strategic leadership skills for managing key functions in pharmaceutical R&D and provides a platform for life-long professional and personal network in the industry.”

# 2

## Modul 2



**Mrs Sanaz Afrouznia,**  
Scientific Associate,  
Novartis Pharma

"I was impressed by famous speakers from all over the world and I appreciate getting to know people from different functions in drug development. ECPM has broadened my knowledge and perspective in drug development."

February 10 – February 13, 2020

## From Non-Clinical Testing to First-in-Human

### Content

Prioritising areas of therapeutic interest and target product profile. Principles for target identification, understanding of combinatorial chemistry and drugability of new compounds. Exploring possible new drugs by means of preclinical safety and efficacy testing. The choice and the predictive value of animal testing for toxicity data as well as the principles of ADME, possibilities and opportunities of computer assisted modelling on the way to proof of concept. Procedures and databases for pharmaco-vigilance and pharmacoepidemiology surveillance. Pharmaceutical engineering and choice of formulation.



### Key topics

- Non-clinical testing for chemical and biological compounds, including pharmacology (ADME) and toxicology
- Development, testing and formulation of chemical and biological compounds
- Non-clinical testing requirements prior to First-in-Human studies
- Molecular and cellular basis of toxicological reactions
- Genetic and genomic factors in drug development and drug response
- Transition from non-clinical to First-in-Human studies
- Clinical pharmacology and application to clinical development

### Learning outcomes

At the end of this Module the student should be able to describe the:

1. Value of non-clinical testing programmes and their integration into the overall drug development plan
2. Steps in the pharmaceutical development of a drug substance
3. Principles of clinical pharmacology and their application to clinical development
4. Requirements, planning and regulations of non-clinical and First-in-Human studies

June 22 – June 25, 2020

## Planning, Collecting and Managing Clinical Data

### Content

The planning, the choice of different trial designs, the randomisation modes and the choice of endpoints are discussed. The different aspects of the conduct of a trial, i.e. study monitoring, principles of good clinical practice (GCP), adverse event monitoring (risk/benefit assessment) and data management are demonstrated. A basic introduction to biostatistics is given.

### Key topics

- Early studies in patients: dose-finding / proof of mechanism studies
- Confirmatory clinical development plan
- Different types of clinical studies, including placebo controlled studies
- Planning and managing clinical trials
- Planning of clinical trial supplies for test substance and comparators
- Legislative requirements and Good Clinical Practice (GCP) in the clinical trial process
- Investigator and site recruitment, investigative site management and conflict resolution
- Statistical considerations in the design of clinical trial protocols and analysis of clinical trial data
- Procedures for clinical trial data collection and data management

### Learning outcomes

At the end of this module the student should be able to outline the:

1. Management of early studies in patients and their impact on the drug development plan
2. Design of various types of clinical studies and statistical methods used
3. The confirmatory clinical development plan including the role of relevant study committees
4. Key issues involved in the conduct of a clinical study in terms of Good clinical Practice (GCP)



# 3

Modul 3



**Mrs Denise Lee, Head  
Clinical Operations,  
Bencard Allergie GmbH**

“With resources, funds and patients being limiting factors to execution of studies, a holistic view of drug development is essential. The ECPM diploma course is my ticket to this deeper understanding!”

# 4

## Modul 4

September 7 – September 10, 2020

### Clinical and Safety Data Evaluation and Biostatistics

#### Content

The different tests and methods of biostatistics are discussed. The application of different trial designs is simulated, within-trial decisions, data management, extraction, manipulation and storage of data.

#### Key topics

- Development of a clinical trial protocol and the investigator drug brochure (IDB)
- Quality management issues in clinical trials
- Legal and ethical provisions for protection of clinical trial subjects
- Statistical methods used in clinical research
- Collection and evaluation of adverse event data in clinical trials
- Drug safety monitoring board and other relevant study committees
- Evaluation and interpretation of clinical trial results

#### Learning outcomes

At the end of this Module the student should be able to describe the:

1. Development of a clinical trial protocol and the role of the investigator drug brochure (IDB)
2. Principles and practical relevance of ethical and legal issues in biomedical research
3. Evaluation and interpretation of clinical trial results
4. Main statistical methods used in clinical data analysis
5. Collection and evaluation of adverse event data in clinical trials



**Professor Robert O'Neill,**  
Teaching Faculty,  
former Director Office of  
Biostatistics FDA, USA

"ECPM continues to be a premier program for integrated knowledge on the life cycle of global pharmaceutical development and regulation"

February 1 – February 4, 2021

## Global Registration and Approval Process

### Content

Overview on mechanisms and regulatory management systems in Europe, the USA and Asia. Requirements of a regulatory application, documentation and collaboration between developers and regulators. Special regulatory procedures, strategies and crisis management.

### Key topics

- Regulation of pre- and post-approval of medicines at EU and global level
- Regulatory activities within a pharmaceutical company
- Labelling requirements
- National and international bodies responsible for medicines regulation and their procedures
- Appeal and Referral
- Off-label/unlicensed use of medicines
- International Conference on Harmonisation (ICH)
- Common technical document (CTD)
- Special Interest Area Community (SIAC)
- Pharmacovigilance: Classification of adverse events/reactions
- Safety reporting requirements pre- and post-approval
- Benefit/risk assessment and pharmacoepidemiology throughout the lifecycle of a medicine

### Learning outcomes

At the end of this module the student should be able to outline the:

1. General principles of medicines and medical devices regulation (both pre- and post-approval)
2. Principles and management of drug safety and pharmacovigilance
3. Role of pharmacoepidemiology in the lifecycle management of a medicine



# 5

Modul 5



**Sir Alasdair Breckenridge,  
Teaching Faculty, Former  
Chairman of UK Medicines  
and Healthcare Regulatory  
products Agency MHRA, UK**

“For the past 25 years, ECPM has provided high quality training in regulatory science to generations of young scientists from industry and academia at critical stages of their careers. The quality of the teachers and of the students just increases every year and is testimony to its success. It has given rise to similar courses in China and the United States where the format of the course has proven to be of inestimable value.”



# 6

## Modul 6

June 21 – June 24, 2021

### Integrated Product Development, Healthcare Marketplace and Marketing

#### Content

Principles of project and portfolio management, including aspects of planning, project evaluation and decision making. Management structure and organisation of clinical development. Team work and performance assessment. Interaction between project teams and business. How to place a new drug successfully into the market.

#### Key topics

- Principles and regulations of drug marketing
- Good Promotional Practice: ethical and legal principles pertaining to marketing activities
- Health economics and health technology assessment (HTA)
- Patient Organisations
- Life cycle management
- Strategic considerations of portfolio management

#### Learning outcomes

At the end of this Module the student should be able to describe the:

1. Principles and practice of the quality system of drug lifecycle activities
2. Ethical and legal principles of market introduction of a drug
3. Principles and practical application of health economics and health technology assessment (HTA) within the healthcare marketplace



**Dr Anand Jain, ECPM  
Diploma Graduate and  
Master in Medicines  
Development And Senior  
Medical Manager, Novo  
Nordisk Healthcare AG**

“The ECPM courses are developed such that participants are always kept engaged and seek their active participation throughout. I thoroughly enjoyed my education and I am convinced that ECPM is the premier institute for Pharmaceutical professionals.”

# Teaching Format Diploma Modules

## Combine onsite training and online follow up.

### Learning methods

---

All lectures are video recorded and can be viewed together with the PowerPoint slides on the protected ECPM website. These files can be viewed on computers, iPads, tablets and smart phones. Students are personally responsible for preparing for the final examination. The learning process of the course includes didactic teaching and places a great emphasis on interactive participation. Each module includes the following activities:

#### Lectures

State-of-the-art lectures and updates on important drug, diagnostic and therapeutic areas and issues, followed by in-depth discussions.

#### Case Studies

Participants work in small interdisciplinary teams on 'real-life cases'. Problems are analysed and discussed together with faculty members. Participants try to reach a common strategy, which is then presented and defended in a roundtable discussion. Three weeks prior to each module you will be able to download the documents and the background literature from our website in order to prepare yourself. We expect you to read the material in advance, in order to be able to actively discuss the problems.

#### Continuing Education Seminars – 'Frontiers in Drug Development'

These seminars on day four of the course module are an integral and mandatory part of the ECPM course and in addition open to alumni and other professionals who are looking for continuing education in this field.

#### ECPM website / mediathek

Documents, on e-book, videos and self-testing are available for course participants on the ECPM website. You need to log in under my ecpm.

**The course language is English.**

### Course materials

---

All students get online access to the teaching material on the first day of the course. Additionally you can buy course binders including summaries, reference list and the slides of each lecture in paper.

The cost of the paper version is CHF 500 and the folder will be provided on the first day of each module.

### Mediathek

---

If you have missed some lectures or like to re-visit or repeat course content you have the unique opportunity to watch the speakers in a video. The video is linked with the PowerPoint slides to simulate the real time lecture. In addition a short summary or review article embracing the topic is available besides the pdf of the slides.

To test yourself and to familiarise with the type of multiple choice questions of the final examination for each module a short self-assessment is available.

A special feature is the availability of the online book "Grays Medicines Development" by Dr. Julian Gray. It summarises the key aspects of the Pharma-Train syllabus representing the whole drug development process.



#### Number of students

(1991–2018)

**1918**




#### Nationalities of students

(2017–2019)

**31**

# Registration and Tuition Fee

## Become a student at the University of Basel.



### Educational Background of Students

(2017–2019)

MD	25 %
PhD	26.9 %
MD, PhD	3.7 %
MBA, Business	4.6 %
MSc Pharm. Sciences	10.2 %
MSc Life Sciences	17.6 %
MA Linguistics	0.9 %
BSc Life Science	8.3 %
others	2.8 %

Total 100 %

Total no of students 108

### Diploma Course

The tuition fee for the entire diploma course amounts to CHF 14'750. A reduced fee of CHF 13'750 applies to continuing training centres and for companies who register more than 10 participants. The special fee for nonprofit organisations is CHF 9'000.

The tuition fee includes matriculation at the University of Basel, online course material, access to the online mediathek, fee for the MCQ examination, lunches, coffee breaks and welcome aperitif.

The entire tuition fee is payable on confirmation of attendance by June 30, 2019. Upon request, the payment may be made in two instalments, first payment on June 30, 2019 and second payment on June 30, 2020.

### Master Course

After starting the diploma course you can register for the master course at any time and start collecting additional credit points. The maximum study time to qualify for the master's degree is five years. The individual master modules differ in price and institution while the scientific guidance and defence of the master thesis at the University of Basel implies a fee of CHF 3'500.

	CAS	DAS	MAS	Swiss Specialist in PM or SwAPP Diploma	CPD
<b>6 Diploma Modules</b>	14'750	14'750	14'750	14'750	
<b>Groups and training centres</b>	13'750	13'750	13'750	13'750	
<b>Non for profit organisations</b>	9'000	9'000	9'000	9'000	
<b>Printed course material</b>	500	500	500	500	
<b>MCQ Examination Retake</b>	– 500	– 500	– 500	– 500	
<b>Oral/Essay Examination Retake</b>	na	750 750	750 750	750 750	
<b>Single or individual modules</b>	na	na	750 – 3000	na	750 – 3000
<b>Master thesis</b>			3'500		
<b>Total</b>	14'750	15'500	about 25'000 depending on choice of modules	15'500 plus registration with professional association	na

Tuition fees in CHF / Prices 2018 (can be subject to change)

## Registration

---

Registrations are reviewed and will be confirmed on an ongoing basis. Deadline for application is March 31, 2019. As enrolment is limited, prospective participants are encouraged to apply well in advance. Registration can be done via the internet: [www.ecpm.ch/application-diploma/](http://www.ecpm.ch/application-diploma/)

ECPM course participants will be registered as students at the University of Basel is included. To obtain the student card a separate form (requiring a printed photo) will be provided by the university. A strong command of English is necessary to comprehensively follow the course.

Applications together with a one two-page curriculum vitae and a copy of the University diploma (or a certified English or German translation) should be submitted to:

ECPM  
Beatrice Schmid  
Institute of Pharmaceutical Medicine  
University of Basel  
Klingelbergstrasse 61  
CH-4056 Basel, Switzerland

Phone +41 61 207 1950  
E-mail [ecpm@unibas.ch](mailto:ecpm@unibas.ch)  
Web page [www.ecpm.ch](http://www.ecpm.ch)

## Cancellation policy

---

Notification of cancellations must please be in writing and emailed to [ecpm@unibas.ch](mailto:ecpm@unibas.ch).

In case of cancellation after June 30, 2019, the tuition fee less CHF 750.– for administrative expenses will be returned.

Participants who do not attend the course on the scheduled date are considered no-shows and will be invoiced the full course fee.

## Course venue

---

Medical Faculty: Institute of Pathology,  
University of Basel, Hebelstrasse/  
Schönbeinstrasse 40, Basel, Switzerland  
and  
Department of Pharmaceutical Sciences.  
Pharmacenter, University of Basel  
Klingelbergstrasse 50, Basel, Switzerland

Bus to “Basler Kinderspital UKBB” from Basel SBB railway station and Badischer Bahnhof No 30

From Airport Basel-Mulhouse: Bus No 50 to Basel SBB railway station, then change to Bus No 30  
Walking distance from Marktplatz: 15 minutes

## Accommodation

---

Accommodation for the course modules is not included in the tuition fee. Hotels have to be booked individually. We can offer a reduced rate for some hotels. Please contact [ecpm@unibas.ch](mailto:ecpm@unibas.ch) for more information.



Members of the Course Directorate from left: Beatrice Schmid, Thomas D. Szucs, Annette Mollet, Katja Suter

## ECPM alumni

---

The ECPM alumni club is open to all participants who attended a full course cycle. The alumni are regularly informed about the ECPM activities and are invited to the continuing education seminars at a reduced fee. These events are accredited for continuing professional education.

## Advisory board

---

### Members of the Advisory Board Academia

Dr. Ruth Amstein, Zurich Heart House  
Dr. Gerd Antes, Albert-Ludwigs-University  
Mr. Urs Brügger, University of Applied Science, Bern  
Dr. Rolf Heusser, National Institute for Cancer Epidemiology and Registration (NICER), Zurich  
Dr. Marius Kränzlin, University of Basel  
Dr. Martin Liechti, University of Basel  
Dr. Detlef Niese, former Novartis Pharma AG, University of Basel  
Prof. Martin Schumacher, Albert-Ludwigs-University, Freiburg i. Br.

### Pharma Industry

Dr. Richard Bergström, SICPA  
PD Dr. Patricia Blank, Roche Diagnostics  
Dr. Martine Clozel, Idorsia Pharmaceuticals Ltd.  
Mr. Thomas Cueni, IFPMA  
Dr. David Ebsworth, former Vifor Pharma AG  
Dr. Djordje Filipovic, Novartis Pharma AG  
Mr. Oliver Bleck, Roche Pharma (Schweiz) AG  
Dr. Anthony Man, Novartis Pharma AG  
Dr. Oliver Nayler, Idorsia Pharmaceuticals Ltd.

### Regulator

Dr. Claus Bolte, Swissmedic

## University of Basel

---

### Grand tradition

Founded in 1460, Basel is Switzerland's oldest university. Its students and teachers have included such great minds as the physician and alchemist Paracelsus, mathematicians Jakob Bernoulli and Leonhard Euler, and philosophers Friedrich Nietzsche and Karl Jaspers.

### In the top ten

Leading higher-education rankings such as the "Academic Ranking of World Universities" place the University of Basel among the world's 100 best universities. Within the German-speaking countries, it is one of the top ten in 2016.

### Beacon for life sciences

Life Sciences are the main focal area at the University of Basel, closely linked with Basel's status as a centre of pharmaceuticals and biotechnology and the home of the two large research based pharmaceutical companies Novartis and Roche.







ECPM Cycle XIIV 2017-2019

#### **Imprint**


**Published by**  
ECPM  
Institute of  
Pharmaceutical Medicine  
Klingelbergstrasse 61  
4056 Basel  
Switzerland  
[www.ecpm.ch](http://www.ecpm.ch)

**Design Concept and Layout:**  
atelier w, Basel

**Photography:**  
Page 1:  
Beat Ernst, Basel  
Page 2, 17:  
Ursula Sprecher, Basel  
Page 19:  
Jakob Rohrbach, Arlesheim

**Print:**  
Gremper AG, Basel

All rights reserved. Copies and reproduction of any kind require the permission of the editor.



**Educating  
Talents**  
since 1460.

University of Basel  
ECPM  
Institute of Pharmaceutical Medicine  
Klingelbergstrasse 61  
4056 Basel  
Switzerland  
[www.ecpm.ch](http://www.ecpm.ch)

